ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ONXX Onyx Pharmaceuticals, Inc. (MM)

124.70
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Onyx Pharmaceuticals, Inc. (MM) NASDAQ:ONXX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 124.70 0 01:00:00

Onyx Pharmaceuticals Announces Second Quarter 2007 Financial Results Teleconference and Webcast

31/07/2007 9:00pm

PR Newswire (US)


Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.
EMERYVILLE, Calif., July 31 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will webcast a teleconference with management to discuss second quarter 2007 financial results and provide a general business overview on Tuesday, August 7, 2007, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the second quarter ended June 30, 2007 will be released earlier that day. Interested parties may access a live webcast of the presentation at: http://events.streamlogics.net/conferenceplus/onyx/event002/index.asp or by dialing 847-413-3235 and using the passcode 18558774. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 18558774 approximately one hour after the teleconference concludes. The replay will be available through September 6, 2007. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar is approved for the treatment of advanced kidney cancer in more than 50 countries. For more information about Onyx's pipeline and activities, visit the company's web site at: http://www.onyx-pharm.com/. Nexavar(R)(sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT: Alex Santos of Onyx Pharmaceuticals, Inc., +1-510-597-6504 Web site: http://www.onyx-pharm.com/

Copyright

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart